Mutations in isocitrate dehydrogenase (IDH) define a glioma subset with a favorable prognosis.[4, 17] Gliomas with wild‐type IDH (IDH‐WT) expressed higher TAGLN levels than tumors harboring IDH mutations in the TCGA‐GBM/LGG (low‐grade glioma) RNA‐seq database (Figure 1C). The gene discussed is IDH3A; the disease is central nervous system cancer.